Skip to Content

MetaStat Inc MTST

Morningstar Rating
$0.00 0.00 (9,900.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MTST is trading at a 11% discount.
Price
$0.00
Fair Value
$9.20
Uncertainty
Extreme
1-Star Price
$5.99
5-Star Price
$7.55
Economic Moat
Hdkdfk
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MTST is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.00 / $0.08
Market Cap
$587.74
Volume/Avg
100 / 100

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

MetaStat Inc is a US-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
6

Valuation

Metric
MTST
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
MTST

Financial Strength

Metric
MTST
Quick Ratio
0.15
Current Ratio
0.16
Interest Coverage
−25.67
Quick Ratio
MTST

Profitability

Metric
MTST
Return on Assets (Normalized)
−245.94%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
MTST
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRQvszxptsHtsd$557.8 Bil
VRTX
Vertex Pharmaceuticals IncHqhnfyjSlcxsv$103.3 Bil
REGN
Regeneron Pharmaceuticals IncBkmtczglNvcrjny$98.8 Bil
MRNA
Moderna IncCrfclqrYhx$38.8 Bil
ARGX
argenx SE ADRXwbhjfwLyjnc$21.3 Bil
BNTX
BioNTech SE ADRQvgnljbjkZgjn$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncZpqvbsfrFchcbg$18.4 Bil
BMRN
Biomarin Pharmaceutical IncFhdjlgnpMmrxyq$17.0 Bil
RPRX
Royalty Pharma PLC Class AXjsxxmbwcnGwzkqx$12.4 Bil
INCY
Incyte CorpKlwkfvtTfztrx$11.9 Bil

Sponsor Center